尋夢新聞LINE@每日推播熱門推薦文章，趣聞不漏接❤️
甘肅健順生物科技有限公司（以下簡稱「健順生物」）與隸屬新加坡科技研究局的生物處理科技研究院（以下簡稱「BTI」）達成戰略夥伴關係，共同在新加坡——亞洲生物制藥產業的製造中心和眾多創新生物制藥公司的大本營，建立 CMC 生物製造工藝開發聯合實驗室，以期在整個亞太地區不斷拓展細胞培養基產品和技術開發服務的業務。在此次合作中，依托 BTI 在細胞系工程方面的經驗專長以及上下遊的開發能力，健順生物將進一步加強在該區域內培養基產品的研發和生物製造工藝平台的開發。
Jianshun Biosciences Co. Ltd. (JSBio) today signed a collaboration agreement with Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR), to setup a CMC (Chemistry, Manufacturing and Controls) Biomanufacturing Process Development Lab in Singapore to further accelerate the expansion of JSBio’s cell culture media business and development service support throughout the Asia Pacific region. Singapore is a biomanufacturing hub of Asia and home to many innovative biopharma companies. Throughout the collaboration, JSBio will leverage BTI’s cell line engineering expertise and processing capabilities to further enhance its cell culture media research and biomanufacturing process development platform within the region.
雙方通過此次合作將會在各自生物工藝研究和開發方面的優勢形成互補。健順生物將為本次合作貢獻自身在培養基開發和工藝優化方面的專長技能，與此同時，BTI 將為整個生物制品價值鏈提供背景知識，並配備多重處理技術和內部分析能力。本次合作將使健順生物能夠為亞太地區的潛在客戶提供更高附加值的細胞培養基產品和技術服務。
The partnership will bring together both parties’ complementary strengths in bioprocess research and development. JSBio will provide its expertise in cell culture media development and optimization, while BTI is equipped with a diverse suite of bioprocessing technologies and in-house analytical capabilities for the whole biologics value chain. The collaboration will enable JSBio to provide higher value-added products and services to its potential clients within the Asia Pacific region.
生物處理科技研究院的院長藍康平教授指出：「我們注意到用生物制劑治療人類疾病的需求在迅速增加。 BTI 很高興與 JS Bio 合作並為其發展做出貢獻，結合我們在生物過程和細胞系工程方面的特長，進一步加強細胞培養基研究和生物製造工藝開發，這將有利於生物制劑行業「。
Professor Kong-Peng Lam, Executive Director of BTI, said 「We see an increasing demand for biologics to treat human diseases. BTI is delighted to partner with JS Bio and value-add to their operations, combining our bioprocessing and cell line engineering expertise to enhance cell culture media research and biomanufacturing process development that will benefit the biologics industry」.
甘肅健順生物科技有限公司董事長兼總經理羅順博士提到：「本次合作是健順生物的培養基產品和技術向亞太地區開展國際性推廣的重要一步。我們非常高興能夠與技術經驗豐富的 A*STAR 研究院 BTI 合作，並且堅信雙方可以利用各自的技術專長，為亞太地區提供一個強大的生物製造工藝開發平台。」
Dr Shun Luo, President and Chief Executive Officer of Jianshun Biosciences Co. Ltd. said, 「This collaboration is an important step forward in the international roll-out of JSBio’s cell culture media and technology to the Asia Pacific region. We are very pleased to collaborate with the technical expertise at A*STAR’s BTI and are convinced that we can leverage the technology know-hows from both sides to enable a strong biomanufacturing process development platform that serves the Asia Pacific region.」
生物處理科技研究院簡介/ About the Bioprocessing Technology Institute (BTI)
生物處理科技研究院（BTI）是新加坡科技研究局 (A*STAR)的成員之一，其以生物處理科技研究單位名義創立於 1990 年，於 2003 年更名為生物處理科技研究院。該研究院主要開展專業技術人員的培養，以及與生物工程行業相關的尖端技術開發。一些關鍵研究領域包括表達工藝、動物細胞技術、幹細胞技術、微生物發酵以及下遊純化和分析。如需了解 BTI 更多信息，請訪問公司網站
http://bti.a-star.edu.sg
About the Bioprocessing Technology Institute (BTI) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 1990 as the Bioprocessing Technology Unit, it was renamed the Bioprocessing Technology Institute (BTI) in 2003. The research institute’s mission is to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocessing community. Some of the key research areas include expression engineering, animal cell technology, stem cell research, microbial fermentation, downstream purification and analytics.
For more information about BTI, please visit
http://bti.a-star.edu.sg
甘肅健順生物科技有限公司簡介 /About Jianshun Biosciences Co. Ltd.
健順生物創立於2011年3月，目前已在蘭州、上海、海門建立了符合 cGMP 標準的研發實驗室和生產車間，搭建了具有行業領先水平的細胞培養基研發和製造平台。健順生物專注於研究和開發無血清、化學界定的細胞培養基（包括液體和幹粉），同時提供客戶配方定制開發、生產和上遊工藝技術開發服務。健順生物所提供的國際水平的細胞培養基產品和技術服務，主要用於生物制藥（治療性重組蛋白，包括單克隆抗體）、細胞治療、人用/獸用疫苗的工藝開發和生產。如需了解健順生物更多信息，請訪問公司網站
http://www.jianshunbio.com
Jianshun Biosciences Co. Ltd. (JSBio) was founded in March 2011 and has established laboratories as well as manufacturing plants in Lanzhou, Shanghai, and Haimen according to cGMP Standards, creating an industrial leading platform for research and production of cell culture media. It develops and manufactures serum-free, chemically-defined cell culture media which includes liquid and dry powder form. The company also produces media for stem cells and primary cells. Focusing on research and development, JSBio provides serum-free, chemically-defined cell culture media to biopharmaceutical as well as vaccine companies in China. In addition, JSBio develops customized upstream processes and media formulations for its customers. Its products are mainly used for bio-pharmaceutical (therapeutic recombinant proteins, including monoclonal antibodies), cell therapy, process development and production of human / veterinary vaccines, providing world-class cell culture media and technical services for the biopharmaceutical industry.
For more information about Jianshun Biosciences Co. Ltd., please visit
http://www.jianshunbio.com
版
權
聲
明
本公眾號所有轉載文章系出於傳遞更多信息之目的，且明確註明來源和作者，不希望被轉載的媒體或個人可與我們聯繫([email protected])，我們將立即進行刪除處理。所有文章僅代表作者觀點，不代表本站立場。